Latest Conference Articles

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

View the entire Extraordinary Healer® Award for Oncology Nursing virtual presentation here!

In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.

“Often you think we’re the victim, but there’s a lot that you can do to be your own advocate and participate in your healing,” says stage four metastatic breast cancer thriver Nalie Agustin.

Genetic testing offers a care team a wealth of knowledge to help them craft treatments, but it also can help match patients to clinical trials for potentially better outcomes.

Patients faced with cancer are also faced with tough uphill financial battles, but there are assistance programs that can help.

Having the right understanding and information of a patient’s genetics can not only help treat cancer but also help prevent it.

Understanding a diagnosis is not just something for a patient's care team, the patient needs to understand their diagnosis as well.

Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.

As CDK 4/6 inhibitors become a bigger part of the treatment of breast cancer, CURE® sat down with clinical nurse specialist Patricia Jakel to discuss the essentials about the drug.

Don’t be worried to get a second opinion — it could save your life.

Being a patient with cancer gives you a unique perspective that can become beneficial when serving as an advocate for others.

If patients take a deep breath and concentrate on the journey ahead after receiving a diagnosis, they can find a path forward, says one metastatic breast cancer thriver.

At the 37th Annual Miami Breast Cancer Conference, Dr. Valerie Lemaine discussed the signs and symptoms of BIA-ALCL, as well as how the disease is diagnosed and treated.

At the 2020 CURE® Educated Patient Breast Cancer Summit, oncology nurse Patricia Jakel had the chance to discuss the types of questions patients should be asking their care team.

At CURE’s Educated Patient Breast Cancer Summit, Stephanie Seban shared the ways a patient can become their own best advocate to thrive through their breast cancer journey.

Genetic and genomic testing is vital for patients with breast cancer and not only do patients need to understand why that is, but their physicians as well.

At the 37th Annual Miami Breast Cancer Conference Dr. Jean-Bernard Durand discussed data that showed how prescribed and personalized exercise programs can improve outcomes for patients with cancer who already face a high risk of cardiovascular disease.

“A person becomes a survivor from the point they are diagnosed and for the balance of their lives,” Dr. Don S. Dizon said in a presentation at the 37th Annual Miami Breast Cancer Conference®.

At the 37th Annual Miami Breast Cancer Conference, Dr. Kevin S. Hughes discussed genetic testing and what health care providers should be doing to identify more individuals at risk for cancer.

Xentuzumab in combination with Verzenio, with or without endocrine therapy, may be safe and effective in treating patients with solid tumors and advanced breast cancer.